INTRODUCTION

This case describes the onset of Addison disease in a pregnant woman during the first trimester of a twin pregnancy and gives useful information about the initial and chronic treatment of Addison disease during pregnancy aimed at preserving the mother and fetuses’ health. A 32-year-old woman at 16 + 3 gestational weeks, with celiac disease and Hashimoto thyroiditis, was admitted to the Obstetrics division for persistent vomiting with difficulty feeding, weakness, and mild pelvic pain. At admission, the patient’s blood pressure was 90/60 mmHg and body temperature 35.4°C. Serum sodium was 117 mmol/L. After the hypothesis of undertreated hypothyroidism was discarded, Addison disease was diagnosed, and intravenous therapy with hydrocortisone was initiated. After five days, hemodynamic stabilization and normalization of laboratory tests were obtained. Intravenous therapy was switched to oral hydrocortisone and fludrocortisone. Fetuses’ and mother’s conditions were strictly monitored, and the pregnancy ended at 35 + 2 weeks because of premature rupture of membranes. Newborns were in good health status. Fifteen months after delivery, clinical conditions have improved, and hydrocortisone has been gradually reduced to 25 µg/d. Rapid diagnosis, correct adjustment of glucocorticoid, and mineralocorticoid replacement therapy and fetus and mother’s close monitoring were the critical point of the successful management. Addison Disease is an uncommon, life-threatening condition affecting people at any age, including women during pregnancy. If left untreated, the disease can be rapidly fatal, but the prognosis is good if promptly recognized and hormones are replaced.
1.1 | Case presentation

A 32-year-old Caucasian woman at 16 + 3 weeks’ gestation of a dichorionic, diamniotic twin pregnancy, without a history of smoking or drug abuse, was admitted to the Obstetrics division for persistent severe vomiting with difficult feeding, weakness, and mild pelvic pain. The patient had no significant family history. In 2014, the woman was diagnosed with Celiac disease and lactose intolerance treated by gluten and lactose-free diet. In 2012, she was diagnosed with Hashimoto’s thyroiditis and treated with administration of levothyroxine 475 µg/wk. For failure of embryo attachment at 7 + 4 weeks of gestation, she was treated with 200 mg daily of intravaginal progesterone. Treatment was then shifted to 341 mg of intramuscular 17-α hydroxyprogesterone caproate (Lentogest®) every 3 days for topical intolerance from week 9. She appeared healthy at admission, and physical examination was normal except for low blood pressure (90/60 mmHg) and low body temperature (35.4°C). The heart rate was 100 bpm/min.

1.2 | Diagnostic assessment

Laboratory tests at admission showed serum sodium 117 mmol/L, potassium 4.68 mmol/L, chloride 64 mmol/L. TSH and thyroid hormones showed a well-titrated therapy (TSH 1.19 mU/L (normal range: 0.35-3 mU/L), FT3 4 pg/mL (2.1-4.9 pg/mL), FT4 11.5 ng/L (8-19 ng/L). Vomiting ceased a few hours after the admission, and hyperemesis gravidarum was excluded. Further hormonal tests showed increased plasma-ACTH 648 pg/mL (normal values 8.5-50), plasma-cortisol 14.5 µg/dL (4-25), plasma renin >500 µU/mL (3.3-41), serum aldosterone 65 pg/mL (35-300) in orthostatic and 67 pg/mL (7.5-150) in supine position. Other laboratory tests were normal, except for serum sodium that was persistently low and gradually increased with saline infusion and normalized within six days.

1.3 | Treatment

After the diagnostic hypothesis of adrenal insufficiency arose, the patient was treated with 100 mg of hydrocortisone intravenously three times a day, then 50 mg tid iv because of hyperglycemia. After five days, oral therapy was started with hydrocortisone 10 mg tid plus fludrocortisone 100 µg, up-titrated to 200 µg in 6 days.

1.4 | Outcome and follow-up

The pregnancy proceeded without complications. The patient was clinically stable, with normal plasma electrolytes, glucose, and clinostatic and orthostatic BP. She was admitted to the Hospital for vomiting and diarrhea during the 29th week of pregnancy and was discharged home with the diagnosis of viral gastroenteritis. On that occasion, high dose hydrocortisone was administered (100 mg every 6 hours intravenously) for the first 24 hours; then, the usual oral dosage regimen for corticosteroids was restored and maintained until delivery. Fetal ultrasound examination was normal. Caesarean section for premature rupture of membranes was performed at 35 + 2 weeks without complications, after the iv administration of 12 mg of betamethasone for the prevention of respiratory distress syndrome in the new-born. Two females, 2000 g and 2370 g of weight, presenting normal ultrasound, were born. During labor, the mother was treated with iv hydrocortisone (100 mg bolus), followed by infusion of 200 mg for 24 hours along with fluids administration. Thirty-six hours after delivery, oral therapy was restored at twice the dose taken during pregnancy (hydrocortisone 20 + 20 + 20 mg, fludrocortisone 400 µg). After another day, the dose was reduced to that used in the last weeks of gestation. Five days after delivery, the dosage of fludrocortisone was tapered at 150 µg. One week after the Caesarean section, the patient was discharged home with the following substitutive therapy: hydrocortisone 10 + 5+5 mg + fludrocortisone 150 µg. During the next 5 months, fludrocortisone was gradually reduced to 50 µg/d for edema and low plasma renin. Measurement of serum and urinary cortisol showed that celiac disease did not affect hydrocortisone intestinal absorption. After 16 months, serum sodium, potassium, and glucose levels were normal, urinary cortisol was within the normality (70 nmol/die), and serum-cortisol peak level was 636 nmol/L, and therapy was therefore confirmed. The patient reported no difficulties in assuming treatment, and no adverse effects were notable.

2 | DISCUSSION

A crucial point in this patient’s management was the rapidity in recognizing and treating the adrenal insufficiency. The differential diagnosis included at least three other disorders that share the same symptoms and signs: uncontrolled hypothyroidism, hyperemesis gravidarum, and a side effect of progesterone. The first was rapidly ruled-out based on the patient’s clinical features and the normality of thyroid hormones and TSH; additionally, hyponatremia is sometimes associated with hypothyroidism, but this may be mainly in patients with severe primary hypothyroidism and myxedema. Hyperemesis gravidarum was also excluded because vomiting ceased with fluid repletion. Progesterone use can be potentially associated with hyponatremia because it may diminish the effects of aldosterone in the renal tubule and decrease sodium reabsorption.
The coexistence of Addison, Hashimoto, and celiac diseases is consistent with the diagnosis of type II polyglan-
dular autoimmune syndrome, an autoimmune disorder of
polygenic inheritance, and pleomorphic phenotype. The
clinical picture was also challenging because of the twin
pregnancy, lack of recommendation for appropriate clinical
management and the initial replacement therapy during
pregnancy. Current guidelines address the dose adjust-
ment during pregnancy, but initial replacement therapy in
new-onset PAI during pregnancy is not specified. Current
guidelines suggest close monitoring for clinical symptoms
and signs of glucocorticoid excess or under-replacement
therapy at least once per trimester for pregnant patients
with known PAI. During the third trimester, dosage of hy-
drocortisone should be augmented. Hydrocortisone should
be used over cortisone acetate, prednisolone, or predni-
sone because it is not inactivated in the placenta. During
the active phase of labor, a similar dosage to that used in
major surgery is recommended. A case report suggests
rapid glucocorticoid replacement with iv 100-200 mg of
hydrocortisone as a single bolus and 50-100 mg boluses
every 6-8 hours during the acute period. In this case, the
dose of replacement therapy is modulated, primarily based
on serum potassium, serum sodium levels and clinical re-
sponse as assessed by measuring blood pressure and heart
rate. Our clinical case highlights the importance of close
collaborations between different medical specialists (in-
ternal medicine, endocrinology, obstetrics). It is crucial in
detecting and treating such a complex and life-threatening
condition.

ACKNOWLEDGMENT
Authors want to express their special thanks to the patients
who allowed the publication of this clinical case. Published
with written consent of the patient.

CONFLICT OF INTEREST
No conflict of interest to declare.

AUTHOR CONTRIBUTION
Angela Tagetti and Denise Marcon collected clinical and
laboratory data and drafted the manuscript; Cristiano Fava
and Pietro Minuz were involved in drafting the manuscript,
in the diagnosis and in the initial treatment of the disease;
Paolo Moghetti and Giovanna Spiazzi were the patient's
physicians. All the authors contributed to the critical re-
view of the paper.

ETHICAL APPROVAL
Ethical committee Of Verona and Rovigo approved the study
in April 27, 2020 (Project number 2666CE; Protocol number
n. 23 431).

DATA AVAILABILITY STATEMENT
None.

ORCID
Denise Marcon https://orcid.org/0000-0002-1885-2063

REFERENCES
1. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment
of Primary Adrenal Insufficiency: An Endocrine Society Clinical
Practice Guideline. J Clin Endocrinol Metab. 2016;101:364-389.
2. Gagliardi L, Ho JT, Torpy DJ. Corticosteroid-binding globulin: The
clinical significance of altered levels and heritable mutations. Mol
Cell Endocrinol. 2010;316:24-34.
3. Schrier RW. Body water homeostasis: Clinical disorders of urinary
dilution and concentration. J Am Soc Nephrol. 2006;17:1820-1832.
4. Derubertis FR, Michelis MF, Bloom ME, Mintz DH, Field JB,
Davis BB. Impaired water excretion in myxedema. Am J Med.
1971;51:41-53.
5. Hanna FW, Scanlon MF. Hyponatraemia, hypothyroidism, and role
of arginine-vasopressin. Lancet. 1997;350:755-756.
6. Randa Hilal-Dandan and LLB Estrogens and Progestins. Goodman
Gilman’s Man. Pharmacol. Ther. 2e.
7. Ambrosi B, Barbetta L, Morricone L. Diagnosis and manage-
ment of Addison’s disease during pregnancy. J Endocrinol Invest.
2003;26:698-702.
8. Singh G, Jialal I. Polyglanular autoimmune syndrome, Type II
(Carpenters, Schmidt). In: StatPearls [Internet]. Treasure Island,
FL: StatPearls Publishing; 2018. Available from: https://www.ncbi.
nlm.nih.gov/books/NBK525992/. Accessed January, 2018.
9. Seaward PG, Guidozi F, Sonnendecker EW. Addisonian
crisis in pregnancy. Case report. Br J Obstet Gynaecol.
1989;96(11):1348-1350.

How to cite this article: Tagetti A, Marcon D, Moghetti P, Spiazzi G, Fava C, Minuz P. Onset of
Addison Disease appeared during the first trimester of
a twin pregnancy: A case report. Clin Case Rep.
2021;9:e03784. https://doi.org/10.1002/ccr3.3784